Mesoridazine (Serentil) in personality disorders--a controlled trial in adolescent patients.
A double-blind study vs. placebo was carried out over a 6-week period in thirty adolescent patients to determine the efficacy and safety of mesoridazine, in the form of 10 mg tablets, in the treatment of symptoms associated with various personality disorders. The average daily dose for the 15 patients in the mesoridazine group was 27.3 mg in the first and 44.7 mg in the sixth week. Mesoridazine relieved anxiety to a highly significant degree when compared with placebo and proved significantly more effective than placebo also in terms of mean improvement scores for depression and hostility. Significant reductions were likewise achieved in the overall severity of the disorders and in the severity of nearly all the other symptoms. The incidence of adverse reactions did not differ significantly from that following placebo administration. No extrapyramidal symptoms were noted.
D000293:Adolescent; D001007:Anxiety / Q000188:drug therapy / Q000209:etiology; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy / Q000209:etiology; D005201:Fantasy; D005260:Female; D005639:Frustration; D006791:Hostility / Q000187:drug effects; D006801:Humans; D008297:Male; D008653:Mesoridazine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010554:Personality Disorders / Q000150:complications / Q000188:drug therapy*; D010919:Placebos; D014705:Verbal Behavior / Q000187:drug effects
D010919:Placebos; D008653:Mesoridazine